首页 News 正文

The reporter learned that Pfizer's innovative drug for treating prostate cancer, Terzena& reg; (TALZENNA®, The generic name: Terazopanib Tosylate Capsules was approved by the National Medical Products Administration (NMPA) on October 29, 2024, in combination with enzalutamide for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult patients with HRR gene mutations. As the only PARP inhibitor approved for mCRPC treatment of HRR gene mutations in China, Taizena& reg; It will help China achieve breakthroughs in precision diagnosis and treatment of prostate cancer, benefiting Chinese prostate cancer patients. (21st Century Business Herald)
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

白云追月素 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    39